Figure 4.
Axi-cel adjusted PFS and OS by V2Vt. Adjusted PFS (A) and adjusted OS (B) by V2Vt in patients treated with axi-cel. Patients were from the CIBMTR registry PASS cohort. For PFS, subsequent cellular therapy and HCT were censored. Covariates for stepwise selection and multivariable adjustment were age, sex, race, ethnicity, ECOG PS before infusion, comorbidities (pulmonary, cardiac/cerebrovascular/heart valve disease, hepatic, and renal), histologic transformation, disease characteristics at initial diagnosis (double/triple hit, disease stage, elevated LDH and >1 extranodal involvement), chemosensitivity before infusion, number of prior lines of therapy, prior HCT, year of infusion, time from initial diagnosis to infusion, and use of bridging therapy.

Axi-cel adjusted PFS and OS by V2Vt. Adjusted PFS (A) and adjusted OS (B) by V2Vt in patients treated with axi-cel. Patients were from the CIBMTR registry PASS cohort. For PFS, subsequent cellular therapy and HCT were censored. Covariates for stepwise selection and multivariable adjustment were age, sex, race, ethnicity, ECOG PS before infusion, comorbidities (pulmonary, cardiac/cerebrovascular/heart valve disease, hepatic, and renal), histologic transformation, disease characteristics at initial diagnosis (double/triple hit, disease stage, elevated LDH and >1 extranodal involvement), chemosensitivity before infusion, number of prior lines of therapy, prior HCT, year of infusion, time from initial diagnosis to infusion, and use of bridging therapy.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal